These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7544169)

  • 1. Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study.
    Frasci G; Comella G; Comella P; Salzano F; Cremone L; Della Volpe N; Imbriani A; Persico G
    Breast Cancer Res Treat; 1995 Aug; 35(2):147-56. PubMed ID: 7544169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women].
    Gladieff L; Houyau P; Mihura J; Martinez M; Caunes N; Chevreau C; Bugat R; Roché H
    Bull Cancer; 1996 Sep; 83(9):703-6. PubMed ID: 8952644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
    Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
    J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer.
    Nisticò C; Garufi C; Barni S; Frontini L; Gallà DA; Giannarelli D; Vaccaro A; D'Ottavio AM; Terzoli E
    Ann Oncol; 1999 Aug; 10(8):937-42. PubMed ID: 10509155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
    Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
    Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma.
    Ibrahim NK; Buzdar AU; Valero V; Dhingra K; Willey J; Hortobagyi GN
    Cancer; 2001 Feb; 91(4):664-71. PubMed ID: 11241232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies.
    Hanna NH; Gordon MS; Fife K; Sandler AB
    Am J Clin Oncol; 2002 Aug; 25(4):337-9. PubMed ID: 12151959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.
    Crawford J; O'Rourke MA
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):73-8. PubMed ID: 7526467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
    Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
    Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly schedule of vinorelbine in pretreated breast cancer patients.
    Nisticò C; Garufi C; Milella M; Vaccaro A; D'Ottavio AM; Fabi A; Pace A; Bove L; Tropea F; Marsella A; Izzo F; D'Attino RM; Ferraresi V; De Marco S; Terzoli E
    Breast Cancer Res Treat; 2000 Feb; 59(3):223-9. PubMed ID: 10832592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
    Ibrahim NK; Rahman Z; Valero V; Murray JL; Frye D; Hortobagyi GN
    Cancer Invest; 2002; 20(1):29-37. PubMed ID: 11852999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer.
    Ingle JN; Kardinal CG; Suman VJ; Veeder MH; Schaefer PL; Kirschling RJ; Mailliard JA
    Breast Cancer Res Treat; 1997 May; 43(3):193-200. PubMed ID: 9150898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
    Esteban E; Modollel A; González de Sande L; Palacio I; Muñiz I; Fernández Y; Corral N; Fra J; Sala M; Vieitez JM; Estrada E; Lacave AJ;
    Breast Cancer Res Treat; 2003 Aug; 80(3):257-65. PubMed ID: 14503798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer.
    Masters GA; Hoffman PC; Hsieh A; Drinkard LC; Mick R; Samuels BL; Guaspari A; Golomb HM; Vokes EE
    J Clin Oncol; 1997 Mar; 15(3):884-92. PubMed ID: 9060524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors.
    Peacock NW; Burris HA; Dieras V; Smith L; Rodriguez GI; Eckardt JR; Jones SF; Hardy J; Hohneker J; Bigley J; Von Hoff DD
    Invest New Drugs; 1998; 16(1):37-43. PubMed ID: 9740542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W
    Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.